Antimyelin Oligodendrocyle Glycoprotein Demyelination
MOG antibody-related disorders, linked to demyelinating conditions like ADEM and NMOSD, ar...
Chronic Relapsing Inflammatory Optic Neuropathy
Chronic Relapsing Inflammatory Optic Neuropathy (CRION) is a rare autoimmune optic neuriti...
Acute Transverse Myelitis
Acute Transverse Myelitis, causing spinal cord inflammation, is treated with high-dose int...
Neuromyelitis Optica
NMOSD, distinct from MS, is marked by AQP4 antibodies causing optic neuritis and myelitis....
PML and JCV titers
Progressive multifocal leukoencephalopathy (PML), caused by John Cunningham virus reactiva...
Multiple sclerosis Spasticity and Pain
Spasticity in MS, manifesting as resistance to movement or involuntary jerks, is managed w...
Multiple sclerosis Cognition and Ambulation issues
Cognitive impairment in MS, manifesting as inattention and memory issues, is managed with...
Multiple sclerosis Bladder and Bowel issues
In MS, neurogenic bladder dysfunction causes urinary frequency and urgency, often worsened...
Multiple sclerosis Tysabri protocol and monitoring
Natalizumab, given as a 300 mg IV infusion every four weeks, can cause infusion reactions,...
Multiple sclerosis Tecfidera protocol and monitoring
Dimethyl fumarate, initially dosed at 120 mg twice daily and then increased to 240 mg, may...
Multiple sclerosis Ocrevus protocol and monitoring
Ocrelizumab, used for B cell depletion, has risks of infusion reactions, infections, and l...
Multiple sclerosis Betaseron protocol and monitoring
Interferon beta-1b for MS is given subcutaneously every other day, with dose titration. Co...
Multiple sclerosis Avonex protocol and monitorin
Interferon beta-1a is administered intramuscularly weekly for MS, starting with a quarter...
Multiple sclerosis SPMS Management
For Secondary Progressive MS (SPMS), active disease management involves switching to treat...
Multiple_sclerosis_PPMS_Criteria
Primary Progressive MS (PPMS) constitutes about 10% of MS cases and is characterized by a...
Multiple sclerosis RRMS When to change disease modifying therapy
Changing Disease Modifying Therapy (DMT) in RRMS is considered for poor response, adherenc...
Multiple sclerosis RRMS Role of antibodies and MRIs for monitoring
Monitoring the response to Disease Modifying Therapies in Relapsing Remitting MS involves...
Multiple sclerosis RRMS Choice of Initial Disease modifying Drugs
Disease Modifying Therapies (DMT) for Relapsing Remitting MS (RRMS) include oral agents (d...
Multiple sclerosis RRMS Latest Diagnostic criteria
Relapsing-remitting MS (RRMS) is diagnosed clinically, typically presenting in young adult...
Multiple sclerosis Basic Management
Multiple Sclerosis, an immune-mediated CNS disease, has no cure but treatments delay progr...